ArchPoint Investors’s Vertex Pharmaceuticals VRTX Stock Holding History

ArchPoint Investors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,500	Closed	-$375K	–	166
2017 Q4	$375K	Sell	2,500 -7,491	-75%	-$1.11M	0.12%	69
2017 Q3	$1.52M	Buy	+9,991	New	+$1.5M	0.48%	33

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

ArchPoint Investors's VRTX Position: Q1 2018 in Review

ArchPoint Investors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2018, closing a stake of 2,500 shares — an estimated $375K sold.

ArchPoint Investors first reported a position in VRTX in Q3 2017 and held it in 2 quarters. The position peaked at $1.52M in Q3 2017. 680 funds tracked by Wall St. Rank hold VRTX as of Q1 2018.

ArchPoint Investors reported no remaining Vertex Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
ArchPoint Investors sold 2,500 Vertex Pharmaceuticals shares in Q1 2018, an estimated $375K.
ArchPoint Investors first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 2 quarters.
ArchPoint Investors's Vertex Pharmaceuticals position peaked at $1.52M in Q3 2017.
680 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2018.

Based on ArchPoint Investors's 13F filing for Q1 2018, filed 14 May 2018.